Skip to Main Content

After the impressive tumor-shrinking data shown by Amgen (AMGN) from its KRAS-targeted cancer drug at the recently completed ASCO meeting, attention — and pressure — now shift to Mirati Therapeutics (MRTX) and its competing KRAS blocker.

Mirati is administering its drug called MRTX849 to patients with solid tumors right now. The first data reveal from the early-stage clinical trial is coming later this year. Mirati isn’t being more precise on timing, but investor expectations are running high, which means this trial readout is now shaping up to be one of the most important stock-moving catalysts remaining on the 2019 biotech calendar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!